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This study aims to validate the current diagnostic method for the clinical detection of gastroenteritis. 
We analyzed 400 stool samples to detect three of the most common enteropathogens: Salmonella 
spp., Campylobacter spp., and Yersinia enterocolitica. All specimens were tested with a routine 
clinical diagnosis algorithm and with five real-time PCR assays. A total of 98 specimens (24.5%) were 
positive for enteropathogens. We found 24 samples positive for Salmonella enterica, 71 positive for 
Campylobacter spp., and 4 positive for Yersinia enterocolitica. All evaluated methods exhibited a good 
performance in identifying Salmonella and Yersinia enterocolitica, being the highest positive percent 
agreement (PPA) value of 95.8% and 100%, respectively. The clinical algorithm showed the highest 
ppA value identifying Salmonella, due to the enrichment in selenite broth. However, the evaluated 
methods showed notable differences in the identification of Campylobacter species, obtaining a wide 
range of PPA values: 59.2%–100%. The clinical algorithm showed the lowest PPA value since it was only 
able to detect Campylobacter jejuni and Campylobacter coli species. This study revealed the importance 
of implementing the real-time PCR technique in a clinical algorithm: it improved the accuracy of the 
diagnosis and provided results in a shorter time compared to routine clinical methods.
Acute gastroenteritis is a leading cause of morbidity and mortality worldwide1, particularly in at-risk popula-
tions, such as children, older individuals, and immunocompromised patients. We included three bacteria in this 
study: Salmonella spp., Campylobacter spp., and Yersinia enterocolitica, which are among the most common enter-
opathogens that cause gastrointestinal infections. Thus, their rapid, accurate identification is crucial for infection 
control, and in selected cases, for determining the most suitable therapy. According to the Centers for Disease 
Control and Prevention, during 2016, the Foodborne Active Surveillance Network identified 24,029 cases of 
foodborne infections, which led to 5,512 hospitalizations (22.9%) and 98 deaths (0.4%). Some of these cases 
were detected by culture, but others were detected with culture-independent diagnostic tests (CIDTs). Current 
CIDTs mainly comprise two types: antigen-based and nucleic acid-based assays. In 2016, one study showed that 
many infections were identified with a CIDT and without a culture confirmation; most frequently, Campylobacter 
(32%) and Yersinia (32%); but also Shiga toxin-producing E.coli (STEC) (24%), Shigella (23%), Vibrio (13%), 
and Salmonella (8%)2. That study revealed the consequences of the current change in diagnostic trends. The 
implementation of CIDTs in clinical laboratories has led to more exhaustive diagnoses. Most of these tests are 
ordered by clinicians, because CIDTs are easier to perform and they return results faster than traditional culture 
techniques. Moreover, samples are subjected to deep screening when multiplex panels are used; consequently, the 
number of reported infections has increased2,3. Routine detection of enteropathogens in clinical laboratories typ-
ically consists of a complex algorithm, based on selective culture-, biochemistry-, and immunology-based tests. 
Most studies have shown that culture-based methods lacked sensitivity, particularly in identifying Campylobacter, 
and most researchers agree that nucleic acid-based CIDTs have great potential. Consequently, CIDTs (particularly 
gastrointestinal panels, based on multiplex real-time PCR technology (qPCR)) are increasingly implemented in 
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clinical laboratories4–8, due to their high sensitivity and their ability to screen a considerable number of enter-
opathogens simultaneously. This approach avoids complex algorithms and reduces the hands-on time. However, 
the use of stool antigen-based CIDTs remains controversial, because they have displayed highly variable sensitiv-
ities and specificities, depending on the study9,10.
This study aimed to compare five molecular CIDTs, based on qPCR technology, to culture-dependent tech-
niques to evaluate their performance and determine the most suitable alternative for routine clinical diagnoses 
of enteropathogens.
Materials and Methods
Study population and clinical stool specimens. Stool samples were submitted from October to December 
2015 to the Hospital Clinico Universitario Lozano Blesa (Zaragoza, Spain). This hospital had 803 beds and attended 
a population of 286,774 inhabitants, with 29,506 admissions annually. It included an outpatient care facility with 
2,315,197 visits annually and an emergency department with 127,694 visits annually. The samples were randomly 
chosen from specimens received with a request for routine detection of enteropathogens (bacteria, virus, and par-
asites). This study was approved by the Clinical Research Ethics Committee of Aragon (25 Sept 2019; PI19/378). 
This evaluation does not require informed consent as it was performed with medical waste. After routine analysis, 
the leftover of DNA, which is considered medical waste, was analyzed with molecular methods. These non-hospital 
routine diagnosis methods implied no risk or burden for any individuals and the patient did not have to provide 
any additional sample. The study focused on the presence/absence of bacterial DNA, without attending to resid-
ual human DNA. For each patient, the following data were collected: gender, age, hospitalization status, and stool 
sample consistency. The non-clinicians researchers never had access to personal identifiable information or clinical 
record. All recorded data were robustly pseudonymized at source, so no subject-identifiable data were generated.
Study design and case definition. Several comparisons were performed simultaneously. All specimens 
were tested with five qPCR assays. In addition, all specimens were analyzed with the routine clinical algorithm. 
Discrepant samples among the qPCR assays were resolved with additional qPCR tests. Discrepancies between the 
qPCR assays and the routine clinical algorithm were resolved with conventional PCR and sequencing.
When an incongruence could not be resolved, the information derived from the other tests was used to resolve 
it. The growth in culture was considered a positive result, regardless of other results.
Consequently, taking into account the above mentioned factors, we designated the following as “cases”:
 a) Samples that were identified as positive in culture media.
 b) Discrepant samples, with positive results supported by resolution tests. We consider as resolution tests 
those that help us to resolve the incongruences. In this study they were the additional qPCR test and the 
conventional PCR and sequencing.
 c) Discrepant samples, without successful resolution tests, but a positive result was supported by at least three 
qPCR assays.
Routine clinical algorithm. Once samples arrived at the Microbiology laboratory, they were routinely 
plated onto various selective and differential media, including selenite broth, MacConkey (MCK) agar, Hektoen 
enteric (HEK) agar, cefsulodin-irgasan-novobiocin (CIN) agar, xylose lysine deoxycholate (XLD) agar, and char-
coal cefoperazone deoxycholate agar (CCDA). These cultures were grown to isolate and identify the enteric path-
ogens. All culture media were obtained from Oxoid (Thermo Fisher Scientific, Massachusetts, US).
Stool samples were inoculated into enrichment selenite broth and incubated at 37 °C for 24 h prior to culturing 
in XLD agar. All media were incubated at 37 °C for 24 h, except for CCDA plates, which were incubated at 42 °C for 
48–72 h under microaerophilic conditions, with a GasPak EZ Campy system (BD Diagnostics, New Jersey, US).
Salmonella is expected to grow on MCK, HEK and XLD agar, Campylobacter on CCDA plates and Yersinia 
enterocolitica on MCK and CIN agar.
Colonies recognized as presumptive pathogens were confirmed with matrix-assisted laser desorption/
ionization-time of flight mass spectrometry (MALDI-TOF MS Biotyper 3.1; Bruker, Massachusetts, US)11 and 
they were further analyzed with an automated system (MicroScan®Neg Combo Type 53 Panel; Beckman Coulter, 
California, US) to determine the sensitivity to antibiotics. Results from the MicroScan® panels were read on the 
MicroScan Walk Away 96 plus platform (Siemens, Munich, Germany).
The species of Campylobacter were determined using MALDI-TOF11.
The serotype of Salmonella was determined following the Kauffmann-White scheme with the Difco 
Salmonella O Antiserum Group Kit (Becton Dickinson, New Jersey, US).
The serotype of Yersinia enterocolitica was determined with the Yersinia enterocolitica O:3 Antiserum Kit 
(BioRad, California, US).
Nucleic acid extraction. Nucleic acids were extracted from fresh stool samples with the VIASURE 
RNA-DNA Extraction Kit (CerTest Biotec S.L., Zaragoza, Spain). Solid (0.1 g) or liquid (200 µl) stool was added to 
200 µl of phosphate-buffered saline, and extraction was performed according to the manufacturer’s instructions. 
Samples were eluted in 100 µl and stored at −20 °C until use in the PCR detection assay.
Real-Time PCR assays. Five different Real-Time PCR assays were evaluated in this study: VIASURE 
Salmonella Real-Time PCR Detection Kit, VIASURE Campylobacter Real-Time PCR Detection Kit, VIASURE 
Yersinia enterocolitica Real-Time PCR Detection Kit, VIASURE Salmonella, Campylobacter & Y.enterocolitica 
Real-Time PCR Detection Kit (CerTest Biotec S.L., Zaragoza, Spain), and RIDA®GENE Bacterial Stool Panel 
(R-Biopharm, Darmstadt, Germany).
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The targets of the three monoplex and one multiplex VIASURE assays are the invA gene (Salmonella), 16S 
rRNA gene (Campylobacter), and ail gene (Yersinia enterocolitica), whereas RIDA®GENE Bacterial Stool Panel 
allows the simultaneous detection of ttr gene (Salmonella), 16S rRNA gene (Campylobacter), and ail gene (Yersinia 
enterocolitica). All Real-Time PCR assays were performed following the manufacturer’s protocol. Positive and 
negative controls were included in each run. All runs were performed on the AriaMx thermocycler (Agilent 
Technologies, California, US).
Real-Time PCR resolution test. The Mericon Campylobacter spp kit (Qiagen, Hilden, Germany) was used 
for resolving Campylobacter discrepant samples. This Real-Time PCR assay was performed according to the man-
ufacturer’s protocol.
Conventional PCR. Conventional PCR was performed with the VIASURE ESSENTIALS DNA Master Mix 
kit (CerTest Biotec S.L., Zaragoza, Spain), according to the manufacturer’s instructions. The kit contained all nec-
essary PCR reagents lyophilized in the wells, except for the primers, which were customizable, depending on the 
target. The primers used for detecting Salmonella (hilA gene) and Campylobacter (16S rRNA gene) were described 
previously12,13; we used 1 µM of each primer. We modified Salmonella primers by deleting the first nucleotides; the 
following forward (5′-ATTTGCGCCATGCTGAGGTAG-3′) and reverse (5′- CCGCCGGCGAGATTGTG-3′) 
primers were used.
PCR products were separated on a 1.0% agarose gel by electrophoresis.
Sequencing. The same conventional PCR primers were used for sequencing. Sequencing was performed by 
the General Research Support Service at the Health Research Institute of Aragon (IIS Aragon) and the University 
of Zaragoza. Sequencing was performed with the capillary sequencer, 3500 XL (Applied Biosystems, California, 
US). Sequences were analyzed with Chromas software, and they were identified with the basic local alignment 
search tool (BLAST; http://www.ncbi.nlm.nih.gov/BLAST/).
Statistical analysis. We compared the tests under study in terms of the positive percent agreement (PPA) 
and negative percent agreement (NPA), instead of sensitivity and specificity. This approach conforms to FDA 
recommendations14, which suggest that sensitivity and specificity should only be used when the comparator 
method is a reference standard. In this study, we did not use the culture as the reference method. Instead, we used 
the “case” definition for the comparator method. Samples were designated “cases” when they were positive in the 
culture media, in the discrepant sample analysis, or at least in three qPCR assays.
The quantification cycle (Cq) value determines the initial copy number of the target. Samples with low target 
concentrations display high Cq values. A Cq value greater than 40 was considered negative.
All statistical analyses were performed with SPSS software (version 22; IBM Corp., Madrid, Spain), except 
for the 95% confidence intervals (CI), which were calculated with the modified Wald method, with GraphPad 
QuickCalcs. The Chi-square test was performed to determine correlations between enteropathogen infections 
and patient groups. A P-value <0.05 was considered statistically significant.
Results
A total of 400 stool samples, acquired from 385 patients, were included in this study. Samples were grouped by 
stool consistency, and they were also classified according to the patient’s age group, gender, and hospitalization 
status. These data are shown in Table 1.
Among 400 stool samples, 98 (24.5%) met the case definition. Of these, 69 were found positive in culture 
media, 25 were discrepant samples that were resolved, and 5 were discrepant samples that were found positive 
at least in three qPCR assays. Although there were 98 cases, there were 99 positive results, because one sample 
corresponded to a co-infection by Campylobacter and Yersinia enterocolitica. A more detailed analysis is given in 
Table 2.
We found 24 cases positive for Salmonella enterica (11 S. Typhimurium, 6 S. Enteritidis, 1 S. Mbandaka, 1 S. 
Braenderup, 1 S. Paratyphi A, 3 S. serogroup G, and 1 Salmonella spp.); 71 cases positive for Campylobacter (39 C. 
jejuni, 7 C. concisus, 6 C. coli, 4 C. upsaliensis, 2 C. hyointestinalis, 1 C. gracilis, 1 C. helveticus, 1 C. curvus, 1 C. 
rectus, and 9 Campylobacter spp); and 4 cases positive for Yersinia enterocolitica O:3. The information of those 
Campylobacter species that were determined by 16 S rRNA sequencing is collected in Table 3.
We could detect most Salmonella positive samples with all methods. The routine clinical algorithm values were, 
as follows: PPA = 95.8%, CI = 78.1–99.9 and NPA = 100%, CI = 98.8–100. The VIASURE and R-Biopharm assays 
provided the same level of results. All gave a PPA = 87.5%, CI = 68.2–96.5 and a NPA = 100%, CI = 98.8–100.
Nine different species of Campylobacter were found. All of these were detected with the VIASURE mon-
oplex assay (PPA = 100%, CI = 93.9–100; NPA = 100%, CI = 98.6–100); the next most accurate assays, in 
descending order were: the VIASURE multiplex (PPA = 95.8%, CI = 87.8–99.0; NPA = 100%, CI = 98.6–100); 
the R-Biopharm (PPA = 81.7%, CI = 71.0–89.1; NPA = 100%, CI = 98.6–100), and finally, the routine clinical 
algorithm (PPA = 59.2%, CI = 47.5–69.8; NPA = 100%, CI = 98.6–100).
The four Yersinia enterocolitica O:3 positive samples could be detected with all methods studied (PPA = 100%, 
CI = 45.4–100; NPA = 100%, CI = 98.8–100).
No false positive results were found in this evaluation; consequently, all NPA values were 100%. Moreover, no 
inhibition occurred in any qPCR reaction; therefore, it was not necessary to re-test any sample.
Samples were grouped according to the Cq value in three categories: Cq <25 (high copy samples), Cq = 25–35 
(medium copy samples) and Cq >35 (low copy samples, near the detection limit). They were also classified into 
two groups: positive by culture and negative by culture. The minimum and maximum Cq values were calculated 
for each group. These data are shown in Table 4. We excluded Yersinia enterocolitica samples that were negative by 
culture as none of them were positive by qPCR assays.
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We also evaluated whether some factors (age, hospitalization status, and stool sample consistency) might be 
positively associated with infections by these three enteropathogens. We performed a Chi-square test, but we 
did not find any statistically significant link between enteropathogen infections and the age group (P = 0.199), 
hospitalization status (P = 0.556), or stool sample consistency (P = 0.073). Hence, we can only report trends. 
When analyzed according to age, most patients affected seem to be the youngest; infection rates were 32.2% in 
pre-school children; 30.6% in infants; 23.1% in school-age children and adolescents; and 20.9% in adults. When 
analyzed according to hospitalization status, infection rates were higher among patients that required hospitaliza-
tion (28.0%), compared to those attended in outpatient clinics (25.1%) and in the emergency department (18.2%). 
Finally, when analyzed according to sample consistency, infections were found most frequently in stools with 
mucous (43.8%), liquid (38.2%), and crumbly (35.7%) consistencies and in stools with traces of blood (28.6%).
Discussion
This study aimed to validate the current routine clinical diagnosis method for identifying the three main 
bacterial enteropathogens: Salmonella, Campylobacter, and Yersinia enterocolitica. We compared the stand-
ard culture-based techniques to three types of qPCR assays (VIASURE monoplex, VIASURE multiplex, and 
R-Biopharm).
In recent years, a large number of studies have been conducted to validate novel gastrointestinal molecular pan-
els as BD Max enteric bacterial panel4, ProGastro SSCS assay7, Allplex GI-Bacteria assay8 or FilmArray GI Panel5,15. 
These previous studies emphasized the importance of not considering the culture technique as the reference 
method, due to its lack of sensitivity. Consequently, we created a reference method based on different techniques. 
According to this reference, samples were classified as “cases” or “non-cases” (see Materials and Methods section).
All methods showed acceptable PPA values (87.5%–95.8%) for identifying Salmonella spp. The highest PPA 
value was obtained with the routine clinical algorithm. This could be explained by the fact that stool samples were 
inoculated into a selenite enrichment broth, as reported in previous studies16. This broth contributed to bacterial 
replication, which enhanced the culture method. The culture method was able to detect samples that showed Cq 
values extremely near the detection limit (Cq > 35).The maximum Cq values obtained in Salmonella identification 
were 39.7, 35.8, and 39.6 with VIASURE monoplex, VIASURE multiplex, and R-Biopharm assays, respectively 
(Table 4). This observation revealed the high sensitivity that could be achieved with the culture method, due to 
the enrichment in selenite broth. We performed qPCR assays to identify Salmonella in two selenite broths whose 
stool sample results were negative with qPCR. As we suspected, the Salmonella DNA could be detected in the 
selenite broth with qPCR assays but could not be detected in the stool sample. The benefits of the Real-Time PCR 
in combination with the enrichment in selenite broth have been recently reported. Boer et al.17 found that the 
number of Salmonella positive samples increased by 2.2% when qPCR was performed after enrichment in selenite 
broth. Tang et al.18 have also validated the high sensitivity and specificity of a national standard protocol based on 
Real-Time PCR combined with guided culture.
Age group No. samples Mean age ± SD
Infants (<2 years) 62 0.9 ± 0.2
Pre-schoolers (≥2 to <5 years) 59 2.7 ± 0.8
School-age children and 
adolescents (≥5 to <18 years) 78 9.3 ± 3.1
Adults (≥18 years) 201 55.8 ± 20.6
Total 400
Gender No. samples Percentage (%)
Female 197 49.3
Male 203 50.8
Total 400 100.0
Hospitalization status No. samples Percentage (%)
Hospitalized 25 6.3
Outpatient 331 82.8
Emergency department 44 11.0
Total 400 100.0
Stool sample consistency No. samples Percentage (%)
Soft 143 35.8
Ordinary 110 27.5
Tough 40 10.0
Liquid 34 8.5
Crumbly 28 7.0
Mucous 16 4.0
With traces of blood 7 1.8
Missing values 22 5.5
Total 400 100.0
Table 1. Characteristics of patients and stool specimens. Abbreviations: No, number; SD, standard deviation.
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Relative to Campylobacter, the qPCR assays exhibited notable differences in their abilities to detect many 
Campylobacter species. The highlight was the high capacities of the VIASURE monoplex and multiplex assays 
(PPA = 100% and PPA = 95.8%, respectively) in diagnosing the majority of Campylobacter species that are con-
sidered pathogenic in humans19.
The R-Biopharm test displayed less diagnostic capacity (PPA = 81.7%). It seems to be due to a failure in the 
recognition of less common Campylobacter species (other than C.jejuni and C.coli) rather than in the sensitivity of 
the test, since most of the samples were in high concentration (Cq < 25). The R-Biopharm assay could not detect 
any positive sample for C. upsaliensis, C. hyointestinalis, C. helveticus, or C. rectus (Table 2).
No. 
Cases
Detection with different assays
VIASURE 
monoplex
VIASURE 
multiplex
R-Biopharm 
multiplex
Conventional 
diagnosticb Resolution test
Salmonella
9 S. Typhimurium, 5 S. Enteritidis, 2 S. serogroup 
G, 1 S. Mbandaka, 1 S. Braenderup,  
1 S. Paratyphi A
19 + + + + N/Ac
1 Salmonella spp 1 + + + − Sequencingd
1 S. serogroup G 1 + + − + N/Ac
1 S. Typhimurium 1 − − + + N/Ac
1 S. Typhimurium, 1 S. Enteritidis 2 − − − + N/Ac
Total 24 21 21 21 23
Campylobacter
35 C. jejuni, 3 C. coli, 3 Campylobacter spp 41 + + + + N/Ac
5 C. concisus, 3 C. jejuni, 2 C. coli, 1 C. curvus,  
1 C. gracilis, 4 Campylobacter spp 16 + + + − Sequencing
e
1 C. jejuni 1 + + − + N/Ac
4 C. upsaliensis, 2 C. hyointestinalis, 1 C. coli, 1 C. 
concisus, 1 C. helveticus, 1 Campylobacter spp 10 + + − − Mericon assay/Sequencing
f
1 Campylobacter spp 1 + − + − Mericong
1 C. concisus, 1 C. rectus 2 + − − − Mericon/ Sequencingh
Total 71 71 68 58 42
Yersinia enterocolitica
4 Yersinia enterocolitica O:3 4 + + + + N/Ac
Total 4 4 4 4 4
Table 2. Comparison of different molecular assays and the routine clinical method for enteropathogen 
identification. Abbreviations: +, positive detection; −, negative detection; S., Salmonella; C., Campylobacter; N/A, 
not applicable. bConventional diagnostic assays included the culture method, MALDI-TOF mass spectrometry, 
agglutination assays, and biochemical tests. cA discrepancy analysis was not applicable, because these samples 
were positive in culture, which immediately defined them as a “case”. dConventional PCR was unsuccessful; 
therefore, the Salmonella serotype was not resolved in this sample; however, it was considered a “case”, based on 
three diagnostic methods, which supported a positive result. eSequencing was not successful in 4/16 samples, but 
the Mericon assay (the qPCR resolution test) performed with these four samples provided a positive result; thus, 
all were considered “cases”. fAll of these samples were positive in the Mericon assay, and the positive result was 
confirmed with sequencing in 9/10 samples. gThis sample was positive in the Mericon assay. hThese two samples 
were positive in the Mericon assay, and the positive result was confirmed by sequencing in both samples.
No. Samples Identification Identity GenBank Accession
3 C.coli 95–99% NZ_CP007181.1
7 C.concisus 89–99%
CP012541.1
GU255908.1
NC_009802.1
NR_074156.1
1 C.curvus 95% AF550652.1
1 C.gracilis 97% CP012196.1
1 C.helveticus 100% DQ174164.1
2 C.hyointestinalis 98–99% NZ_JHQP01000019.1
3 C.jejuni 99%
NC_002163.1
CP014744.1
1 C.rectus 96% KF030232.1
4 C.upsaliensis 98–99% NR_118528.1
Table 3. Campylobacter species identification by 16S rRNA sequencing.
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Only 3/13 samples that R-Biopharm missed were near the detection limit (Cq > 35) (1 C. concisus, 1 C. rectus 
and 1 Campylobacter spp.); 3/13 showed a Cq = 25–35 (1 C. concisus, 1 C. helveticus and 1 C. jejuni) and 7/13 sam-
ples showed a Cq < 25 (4 C. upsaliensis, 2 C. hyointestinalis and 1 C. coli) (Tables 2, 4).
The routine clinical algorithm was only capable of detecting C. jejuni and C. coli species (PPA = 59.2%) 
(Table 2). This finding was consistent with the literature, where different studies20–22 indicated that some antimi-
crobial agents incorporated into the commonly used selective media (like cefoperazone in CCDA media) could 
inhibit the growth of several species, including C. hyointestinalis, C. upsaliensis, and C. fetus. Moreover, not all 
Campylobacter species are thermophilic; consequently, the incubation at 42 °C was not suitable for all species. 
Additionally, some species, like C. concisus, C. rectus, C. curvus, C. gracilis, and C. showae require a special atmos-
phere enriched with hydrogen.
The culture technique failed to detect 3 C. jejuni and 3 C. coli samples (Table 2). None of them were low copy 
samples since 4/6 showed values of Cq < 25 and 2/6 showed a Cq value = 25–35. This observation revealed that 
sometimes even the growth of C. jejuni and C. coli in selective media could be complicated.
For the above reasons, the qPCR technique appears to be a reliable solution for Campylobacter identification 
since it could ensure the identification of most Campylobacter species without excessive complications in the 
diagnostic algorithm.
Regarding Yersinia enterocolitica, all the methods studied could detect all samples positive for Yersinia enterocolitica 
O:3 (PPA = 100%).
An important aspect of this study was that no false positive result was found in any qPCR assay. This high spec-
ificity (100%) could represent a key difference between molecular-based and antigen-based CIDTs. Couturier10 
stated that the problem with stool antigen-based CIDTs was that they exhibited highly variable sensitivities and 
specificities. That problem has not occurred with molecular-based CIDTs, which, to date, have shown excellent 
sensitivity and specificity compared to cultures. Our findings correlate with those previous results; therefore, 
molecular CIDTs could be considered a reliable diagnostic tool, although more studies are needed. Additionally, 
some molecular CIDTs, like VIASURE assays, are very easy to use. All the components are provided lyophilized 
inside the wells, which implies that the user is not required to mix any reagents. Also, the lyophilized format facil-
itates the storage and shipping conditions as lyophilized reagents are stable at room temperature.
We did not encounter inhibition in any of the qPCR assays, although we tested a vast range of stool consisten-
cies. This finding suggested that the qPCR assays used in this study are robust tests with a stable matrix formula-
tion, which neutralized PCR inhibitor effects.
The main limitation of this study was that the number of positive samples depended on the prevalence of each 
pathogen in the study area. Consequently, we recommend that a multicenter study should be performed, and that 
the sample collection time should be extended.
We conclude that the three types of qPCR assays (VIASURE monoplex, VIASURE multiplex and R-Biopharm) 
tested could improve the routine clinical diagnosis algorithm, because they had a noticeable impact on the 
Campylobacter diagnosis. Additionally, they exhibited good performance in Salmonella and Yersinia enterocolitica 
identification too, and they substantially reduced the turnaround time (from days to hours). The ease of using 
molecular methods and the time they save will allow laboratories to increase the number of samples processed. 
Moreover, saving time is critical for avoiding the spread of infections and for providing effective treatment plans.
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